tetano
Editor, Senior Moderator
Geroscience
. 2022 May 11.
doi: 10.1007/s11357-022-00582-8. Online ahead of print.
Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19?
Henrietta Papp[SUP] 1 2 [/SUP], Zsófia Lanszki[SUP] 3 4 [/SUP], György M Keserű[SUP] 5 [/SUP], Ferenc Jakab[SUP] 3 4 [/SUP]
Affiliations
Abstract
Since the appearance of coronavirus disease 2019 (COVID-19), numerous studies have been conducted to find effective therapeutics. Favipiravir (FVP) is one of the repurposed drugs which has been authorized in a few countries on an emergency basis to treat COVID-19. Elderly individuals especially 65 years or older are more prone to develop severe illness. We aim to provide a short summary of the current knowledge of the antiviral efficacy of favipiravir with respect to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected elderly patients. We found that it is rather controversial whether favipiravir is effective against SARS-CoV-2 infection. Data regarding patients 65 years or older is not sufficient to support or reject the usage of favipiravir for COVD-19 treatment. Further studies would be advisable to elicit the efficiency of favipiravir in elderly COVID-19 patients.
Keywords: Clinical trials; Geriatrics; Severe acute respiratory syndrome coronavirus 2; T-705.
. 2022 May 11.
doi: 10.1007/s11357-022-00582-8. Online ahead of print.
Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19?
Henrietta Papp[SUP] 1 2 [/SUP], Zsófia Lanszki[SUP] 3 4 [/SUP], György M Keserű[SUP] 5 [/SUP], Ferenc Jakab[SUP] 3 4 [/SUP]
Affiliations
- PMID: 35543795
- DOI: 10.1007/s11357-022-00582-8
Abstract
Since the appearance of coronavirus disease 2019 (COVID-19), numerous studies have been conducted to find effective therapeutics. Favipiravir (FVP) is one of the repurposed drugs which has been authorized in a few countries on an emergency basis to treat COVID-19. Elderly individuals especially 65 years or older are more prone to develop severe illness. We aim to provide a short summary of the current knowledge of the antiviral efficacy of favipiravir with respect to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected elderly patients. We found that it is rather controversial whether favipiravir is effective against SARS-CoV-2 infection. Data regarding patients 65 years or older is not sufficient to support or reject the usage of favipiravir for COVD-19 treatment. Further studies would be advisable to elicit the efficiency of favipiravir in elderly COVID-19 patients.
Keywords: Clinical trials; Geriatrics; Severe acute respiratory syndrome coronavirus 2; T-705.